Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The study is a randomized, double blind, placebo-controlled, parallel-group comparison (two
dose levels of EMA401 versus a placebo group), of safety and efficacy in patients with
postherpetic neuralgia.